The Effectiveness of UVA1 and UVB Irradiation in the Treatment of Inflammatory Dermatoses: An Open Pilot Study
The purpose of this investigation is to study the effectiveness of longer wavelength UVA1
(340-400nm) or shorter wavelength UVB (290-320nm) irradiation in the treatment of
inflammatory skin conditions. Inflammatory dermatoses refer to conditions like atopic
dermatitis (eczema) and psoriasis in which circulating leukocytes (T cells, neutrophils, and
monocytes) infiltrate the skin. The infiltrating cells may be of malignant phenotype as in
mycosis fungoides (cutaneous T cell lymphoma-CTCL). Up to 50 patients with one of these
diagnoses or related conditions will participate in this study. The affected areas on the
body will be treated with UVA1 or UVB for up to 5 times per week for 16 weeks. The UVA1 dose
will be up to 130 J/cm2. The maximum UVB dose will be 4000 mJ/cm2. This UVA1 dosing
schedule has been safely used in Germany for treating patients with atopic dermatitis,
mycosis fungoides, granuloma annulare, scleroderma, and urticaria pigmentosa. Subjects will
be evaluated clinically at baseline, weeks 1, 2, 4, and then at monthly intervals. More
frequent evaluation may be required depending on the condition being studied. Paired skin
biopsies may be taken from involved and uninvolved (or treated and untreated) areas before
and during UV therapy.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Clinical assessment to determine the effectiveness of light treatment for skin condition
Subjects will be evaluated at weeks 1, 2, and 4, then every month until the end of the study
No
John J Voorhees, MD
Study Chair
University of Michigan
United States: Institutional Review Board
Derm 446
NCT00129415
August 2000
January 2011
Name | Location |
---|---|
University of Michigan Department of Dermatology | Ann Arbor, Michigan 48109 |